Lynn Rothman Sells 6,000 Shares of Penumbra Inc (PEN) Stock

Penumbra Inc (NYSE:PEN) EVP Lynn Rothman sold 6,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $90.99, for a total transaction of $545,940.00. Following the transaction, the executive vice president now directly owns 159,519 shares of the company’s stock, valued at approximately $14,514,633.81. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Penumbra Inc (PEN) traded up $0.65 during midday trading on Thursday, hitting $90.10. 299,855 shares of the stock traded hands, compared to its average volume of 403,350. The stock has a market cap of $2,959.45, a PE ratio of -409.55, a price-to-earnings-growth ratio of 93.43 and a beta of 0.16. Penumbra Inc has a 52-week low of $67.95 and a 52-week high of $116.35.

Penumbra (NYSE:PEN) last announced its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.07. The firm had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $79.17 million. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The business’s revenue was up 24.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.04) EPS. equities research analysts predict that Penumbra Inc will post -0.15 earnings per share for the current fiscal year.

PEN has been the subject of several research reports. JPMorgan Chase & Co. downgraded shares of Penumbra from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Zacks Investment Research raised shares of Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Canaccord Genuity increased their price objective on shares of Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Finally, BMO Capital Markets increased their price objective on shares of Penumbra from $96.00 to $117.00 and gave the company an “outperform” rating in a report on Wednesday, November 8th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $111.50.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Penumbra by 10.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock valued at $102,000 after buying an additional 114 shares in the last quarter. Simplex Trading LLC raised its position in shares of Penumbra by 116.2% during the 4th quarter. Simplex Trading LLC now owns 1,911 shares of the company’s stock valued at $179,000 after buying an additional 1,027 shares in the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Penumbra during the 3rd quarter valued at about $214,000. Verition Fund Management LLC purchased a new stake in shares of Penumbra during the 2nd quarter valued at about $213,000. Finally, Ameritas Investment Partners Inc. raised its position in shares of Penumbra by 10.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock valued at $226,000 after buying an additional 250 shares in the last quarter. Hedge funds and other institutional investors own 71.71% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Lynn Rothman Sells 6,000 Shares of Penumbra Inc (PEN) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/18/lynn-rothman-sells-6000-shares-of-penumbra-inc-pen-stock.html.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply